Diagnosis
Diabetes linked to cognitive decline in mothers and neurodevelopmental risks in children

Gestational diabetes is tied to cognitive decline in mothers and higher risks of autism and ADHD in children, according to new research.
The ongoing systematic review and meta-analysis covered 48 observational studies involving more than 9m pregnancies across 20 countries, with data included up to April 2024.
It found clear cognitive impacts for both mothers and children.
Researchers at the National University of Singapore reported that mothers with gestational diabetes scored 2.47 points lower on cognitive assessments than those without the condition.
Gestational diabetes is high blood sugar that develops during pregnancy, affecting about 14 per cent of pregnancies worldwide.
Children born to affected mothers scored an average of 3.92 points lower on IQ tests and had a 3.18 point reduction in verbal crystallised intelligence – the ability to understand, analyse and communicate effectively through language.
The analysis also showed children faced a 45 per cent higher risk of developmental delay, a 36 per cent greater likelihood of attention-deficit/hyperactivity disorder (ADHD), and a 56 per cent higher risk of autism spectrum disorder (ASD).
Dr Ling-Jun Li from the School of Medicine, National University of Singapore, said: “There are increasing concerns about the neurotoxic effects of gestational diabetes on the developing brain.
“Our findings underscore the urgency of addressing this significant public health concern that poses substantial cognitive dysfunction risks for both mothers and offspring.”
The condition usually resolves after birth but can still cause complications.
Mothers face higher risks of high blood pressure and caesarean delivery, while children have increased risks of premature birth, large birth weight and neonatal hypoglycaemia (low blood sugar in newborns). Children are also more likely to develop obesity and diabetes in adulthood.
Women who are obese, older mothers, those from non-white backgrounds and those with a family history of diabetes are at greater risk of developing it.
Although the exact mechanisms remain unclear, researchers suggest factors such as inflammation, stress in cells, reduced oxygen supply and high insulin levels may affect the baby’s brain development in the womb.
The Montreal Cognitive Assessment used in the study tests functions such as memory, attention and problem-solving, with a maximum score of 30.
The meta-analysis found no major differences in overall brain structure or general cognitive scores between affected and unaffected children.
Presenting author Caitlin Por, a medical student at Monash University in Melbourne, Australia, said: “Longer follow-ups across childhood are also needed to examine whether these associations persist or progress further to other worse outcomes.”
The authors stressed the need for early screening and careful management to limit neurocognitive complications in mothers and children.
Further research is needed to establish causality and clarify the links between gestational diabetes and the full range of cognitive outcomes.
Pregnancy
Home blood pressure checks could lower heart risks for new mothers – study
Diagnosis
Researchers teach AI to spot cancer risk by squeezing individual breast cells
Diagnosis
Experimental drug drowns triple-negative breast cancer cells in toxic fats

An experimental drug slowed triple-negative breast cancer in mice by flooding tumour cells with toxic fats.
Triple-negative breast cancer lacks three common drug targets, making it one of the hardest-to-treat and most aggressive forms of the disease.
The compound, known as DH20931, appears to push cancer cells past their limits by triggering a surge in ceramides, fat-like molecules that place the cells under intense stress until they self-destruct.
In lab experiments, the drug also made standard chemotherapy more effective. When combined with doxorubicin, researchers were able to reduce the dose needed to kill cancer cells by about fivefold.
The drug targets an enzyme known as CerS2 to sharply increase production of these lipids and stress cancer cells. Healthy cells, by contrast, showed lower sensitivity to the drug in lab tests.
While the early results are promising, further preclinical and clinical trials would still be needed to determine the safety and effectiveness of DH20931 in humans.
Satya Narayan, a professor in the University of Florida’s College of Medicine, led the study with an international group of collaborators.
The researchers published their results on human-derived tumours on 21 April and presented their findings on combination therapy at the annual meeting of the American Association for Cancer Research in San Diego.
Narayan likened the drug’s effects to a home’s electrical system handling a power surge.
While healthy cells act like a properly grounded and installed circuit, cancer cells are more like a jumble of mismatched wires and faulty fuses. DH20931 overwhelms cells not with electricity, but with fats.
He said: “When that surge goes into the cancer cells, they cannot handle the amount of power they are getting. The fuses burn out, the cell can’t handle the surge and it dies.”
The compound was developed at the University of Florida in the lab of Sukwong Hong.
Hong, now a professor at the Gwangju Institute of Science and Technology in South Korea, created DH20931 as one of many drug candidates tested for efficacy in Narayan’s lab.
In the study, researchers implanted human triple-negative breast cancer tumours into mice and treated them with DH20931.
The drug significantly slowed tumour growth without causing noticeable weight loss or signs of toxicity in the animals. In separate lab experiments, it also showed activity against other breast cancer subtypes.
In addition to increasing lipid levels, DH20931 triggers a second stress signal by flooding cells with calcium.
Together, these effects disrupt the mitochondria, the structures that produce a cell’s energy, ultimately leading to cell death.
Narayan said: “It does not just follow one pathway but it goes through multiple pathways. It’s a two-hit hypothesis.
“These pathways are common in all breast cancer types and other solid tumours, so we think this drug can be useful not only in triple-negative breast cancer but potentially other cancers as well.”
Entrepreneur6 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Opinion4 weeks agoQ1 momentum: Female founders are advancing, but the system still hasn’t caught up
Diagnosis2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
















